Canada markets closed

PFE Jan 2024 85.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.1300-0.0500 (-27.78%)
As of 10:47AM EDT. Market open.
Full screen
Previous Close0.1800
Open0.2100
Bid0.0800
Ask0.2000
Strike85.00
Expire Date2024-01-19
Day's Range0.1300 - 0.2100
Contract RangeN/A
Volume2
Open Interest1.96k
  • Motley Fool

    Why Biohaven Stock Is Soaring Today

    Shares of Biohaven Ltd. (NYSE: BHVN) were soaring 12.7% as of 11:23 a.m. ET on Tuesday after skyrocketing as much as 21.4% earlier in the day. The big gain came after Pfizer (NYSE: PFE) completed its acquisition of Biohaven Pharmaceutical on Monday. The "old" Biohaven, with its migraine drugs Nurtec ODT and zavegepant, became a wholly owned subsidiary of Pfizer.

  • Zacks

    Why Novavax's (NVAX) COVID Vaccine Struggles for Market Share?

    Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.

  • Business Wire

    Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

    NEW YORK, October 04, 2022--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The study met its primary endpoint with a statistically significant and clinica